Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-25-026970
Filing Date
2025-08-14
Accepted
2025-08-14 16:36:08
Documents
88
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q nby20250630_10q.htm   iXBRL 10-Q 1939467
2 EXHIBIT 31.1 ex_850005.htm EX-31.1 8127
3 EXHIBIT 31.2 ex_850006.htm EX-31.2 8457
4 EXHIBIT 32.1 ex_850007.htm EX-32.1 4150
5 EXHIBIT 32.2 ex_850008.htm EX-32.2 4130
  Complete submission text file 0001437749-25-026970.txt   10704368

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA nby-20250630.xsd EX-101.SCH 94945
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20250630_def.xml EX-101.DEF 639837
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20250630_lab.xml EX-101.LAB 479543
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20250630_pre.xml EX-101.PRE 678326
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nby-20250630_cal.xml EX-101.CAL 37105
91 EXTRACTED XBRL INSTANCE DOCUMENT nby20250630_10q_htm.xml XML 2147775
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33678 | Film No.: 251220142
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)